Literature DB >> 15292271

Identification of novel beta1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1.

Maria J Calzada1, Douglas S Annis, Bixi Zeng, Cezary Marcinkiewicz, Bernhard Banas, Jack Lawler, Deane F Mosher, David D Roberts.   

Abstract

In addition to the three known beta(1) integrin recognition sites in the N-module of thrombospondin-1 (TSP1), we found that beta(1) integrins mediate cell adhesion to the type 1 and type 2 repeats. The type 1 repeats of TSP1 differ from typical integrin ligands in that recognition is pan-beta(1)-specific. Adhesion of cells that express one dominant beta(1) integrin on immobilized type 1 repeats is specifically inhibited by antagonists of that integrin, whereas adhesion of cells that express several beta(1) integrins is partially inhibited by each alpha-subunit-specific antagonist and completely inhibited by combining the antagonists. beta(1) integrins recognize both the second and third type 1 repeats, and each type 1 repeat shows pan-beta(1) specificity and divalent cation dependence for promoting cell adhesion. Adhesion to the type 2 repeats is less sensitive to alpha-subunit antagonists, but a beta(1) blocking antibody and two disintegrins inhibit adhesion to immobilized type 2 repeats. beta(1) integrin expression is necessary for cell adhesion to the type 1 or type 2 repeats, and beta(1) integrins bind in a divalent cation-dependent manner to a type 1 repeat affinity column. The widely used TSP1 function blocking antibody A4.1 binds to a site in the third type 2 repeat. A4.1 proximally inhibits beta(1) integrin-dependent adhesion to the type 2 repeats and indirectly inhibits integrin-dependent adhesion mediated by the TSP1 type 1 repeats. Although antibody A4.1 is also an antagonist of CD36 binding to TSP1, these data suggest that some biological activities of A4.1 result from antagonism of these novel beta(1) integrin binding sites.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292271     DOI: 10.1074/jbc.M406267200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.

Authors:  Samantha Russell; Mark Duquette; Joyce Liu; Ronny Drapkin; Jack Lawler; Jim Petrik
Journal:  FASEB J       Date:  2014-11-13       Impact factor: 5.191

2.  Regulation of Cellular Redox Signaling by Matricellular Proteins in Vascular Biology, Immunology, and Cancer.

Authors:  David D Roberts; Sukhbir Kaur; Jeffrey S Isenberg
Journal:  Antioxid Redox Signal       Date:  2017-09-08       Impact factor: 8.401

Review 3.  Structures of thrombospondins.

Authors:  C B Carlson; J Lawler; D F Mosher
Journal:  Cell Mol Life Sci       Date:  2008-03       Impact factor: 9.261

4.  Peptides derived from type I thrombospondin repeat-containing proteins of the CCN family inhibit proliferation and migration of endothelial cells.

Authors:  Emmanouil D Karagiannis; Aleksander S Popel
Journal:  Int J Biochem Cell Biol       Date:  2007-07-30       Impact factor: 5.085

Review 5.  CD47: a new target in cardiovascular therapy.

Authors:  Jeff S Isenberg; David D Roberts; William A Frazier
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-10       Impact factor: 8.311

Review 6.  Molecular regulation of tumor angiogenesis and perfusion via redox signaling.

Authors:  Thomas W Miller; Jeff S Isenberg; David D Roberts
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

7.  Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain.

Authors:  Barbara Margosio; Marco Rusnati; Katiuscia Bonezzi; Blue-Leaf A Cordes; Douglas S Annis; Chiara Urbinati; Raffaella Giavazzi; Marco Presta; Domenico Ribatti; Deane F Mosher; Giulia Taraboletti
Journal:  Int J Biochem Cell Biol       Date:  2007-10-09       Impact factor: 5.085

8.  The Most N-Terminal Region of THSD7A Is the Predominant Target for Autoimmunity in THSD7A-Associated Membranous Nephropathy.

Authors:  Larissa Seifert; Elion Hoxha; Anna M Eichhoff; Gunther Zahner; Silke Dehde; Linda Reinhard; Friedrich Koch-Nolte; Rolf A K Stahl; Nicola M Tomas
Journal:  J Am Soc Nephrol       Date:  2018-03-19       Impact factor: 10.121

Review 9.  The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia.

Authors:  Anguo Liu; Deane F Mosher; Joanne E Murphy-Ullrich; Simeon E Goldblum
Journal:  Microvasc Res       Date:  2008-10-01       Impact factor: 3.514

10.  Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation.

Authors:  Thomas W Miller; Sukhbir Kaur; Kelly Ivins-O'Keefe; David D Roberts
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.